Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

NCT04032067 is registered in ClinicalTrials.gov with GemVax & Kael as lead sponsor.

NCT NCT04032067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04032067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
Lead sponsor
GemVax & Kael
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2019
Completion date
March 17, 2022
Enrollment
423 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia (bph)